Drug firm Zydus Lifesciences Ltd on Friday (October 24) said it has received a Notice of Compliance (NOC) from Health Canada for its generic Mesalamine suppositories 1000 mg. The product is indicated for the treatment of mildly to moderately active ulcerative proctitis.
The Mesalamine suppositories will be manufactured at Zydus Lifesciences’ facility in Changodar, Ahmedabad, Gujarat. In Canada, Mesalamine suppositories had annual sales of 4.86 million CAD as per IQVIA MAT data for June 2025.
This month, Zydus Lifesciences said it had received a Notice of Compliance (NOC) from Health Canada for its generic Liothyronine tablets in 5 mcg and 25 mcg strengths.
Also Read: Zydus Lifesciences arm launches generic drugs for cats and dogs in US
Liothyronine, a synthetic form of the thyroid hormone T3 (triiodothyronine), is primarily used to treat hypothyroidism. The tablets will be manufactured at Zydus’ Ahmedabad SEZ facility. The product had annual sales of 10.9 million Canadian dollars in Canada, according to IQVIA MAT data for June 2025.
Zydus, including its subsidiaries and affiliates, said the approval will enable it to market the drug in Canada, expanding its footprint in the North American generics market.
Zydus Lifesciences is a diversified Indian pharmaceutical company engaged in the research, development, manufacture, and marketing of a wide range of healthcare products. Its portfolio spans branded formulations, generics, biosimilars, active pharmaceutical ingredients (APIs), vaccines, and over-the-counter products.
Also Read: Zydus Lifesciences gets nod from Health Canada for Liothyronine tablets
Shares of Zydus Lifesciences Ltd ended at ₹1,004.90, down by ₹4.10, or 0.41%, on the BSE.
